-
Exchange | OTCQB |
---|---|
CurrencyCode | USD |
ISIN | US74738N1037 |
Sector | Healthcare |
Industry | Biotechnology |
Market Cap | 37M |
---|---|
PE Ratio | None |
Target Price | None |
Beta | 1.81 |
Dividend Yield | None |
QSAM Biosciences, Inc. engages in developing various nuclear medicines for the treatment of cancer. The company is involved in the development of CycloSam (Samaium-153 DOTMP), a clinical-stage bone targeting radiopharmaceutical. It has a license agreement with IGL Pharma, Inc. The company was formerly known as Q2Earth, Inc. and changed its name to QSAM Biosciences, Inc. in September 2020. QSAM Biosciences, Inc. was incorporated in 2004 and is headquartered in Austin, Texas. As of May 3, 2024, QSAM Biosciences, Inc. operates as a subsidiary of Telix Pharmaceuticals (Us) Inc.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for QSAM using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025